These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25862637)

  • 1. Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein.
    Navis AC; van Lith SA; van Duijnhoven SM; de Pooter M; Yetkin-Arik B; Wesseling P; Hendriks WJ; Venselaar H; Timmer M; van Cleef P; van Bergen En Henegouwen P; Best MG; Wurdinger TD; Tops BB; Leenders WP
    Acta Neuropathol; 2015 Jul; 130(1):131-44. PubMed ID: 25862637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy.
    Zuckermann M; He C; Andrews J; Bagchi A; Sloan-Henry R; Bianski B; Xie J; Wang Y; Twarog N; Onar-Thomas A; Ernst KJ; Yang L; Li Y; Zhu X; Ocasio JK; Budd KM; Dalton J; Li X; Chepyala D; Zhang J; Xu K; Hover L; Roach JT; Chan KC; Hofmann N; McKinnon PJ; Pfister SM; Shelat AA; Rankovic Z; Freeman BB; Chiang J; Jones DTW; Tinkle CL; Baker SJ
    Mol Cancer; 2024 Jun; 23(1):123. PubMed ID: 38849845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal malignancies harbor actionable MET exon 14 deletions.
    Lee J; Ou SH; Lee JM; Kim HC; Hong M; Kim SY; Jang J; Ahn S; Kang SY; Lee S; Kim ST; Kim B; Choi J; Kim KA; Lee J; Park C; Park SH; Park JO; Lim HY; Kang WK; Park K; Park YS; Kim KM
    Oncotarget; 2015 Sep; 6(29):28211-22. PubMed ID: 26375439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
    Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
    J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-410 regulates MET to influence the proliferation and invasion of glioma.
    Chen L; Zhang J; Feng Y; Li R; Sun X; Du W; Piao X; Wang H; Yang D; Sun Y; Li X; Jiang T; Kang C; Li Y; Jiang C
    Int J Biochem Cell Biol; 2012 Nov; 44(11):1711-7. PubMed ID: 22750473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
    Ji F; Liu X; Wu Y; Fang X; Huang G
    Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
    Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
    Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Met is a potentially new therapeutic target for treatment of human melanoma.
    Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
    Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Missense mutation of the MET gene detected in human glioma.
    Moon YW; Weil RJ; Pack SD; Park WS; Pak E; Pham T; Karkera JD; Kim HK; Vortmeyer AO; Fuller BG; Zhuang Z
    Mod Pathol; 2000 Sep; 13(9):973-7. PubMed ID: 11007037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HGF/MET signaling promotes glioma growth via up-regulation of Cox-2 expression and PGE2 production.
    Zhao Y; Sun Y; Zhang H; Liu X; Du W; Li Y; Zhang J; Chen L; Jiang C
    Int J Clin Exp Pathol; 2015; 8(4):3719-26. PubMed ID: 26097553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of MET genomic amplification, protein expression and alternative splice isoforms in neuroblastomas.
    Yan B; Lim M; Zhou L; Kuick CH; Leong MY; Yong KJ; Aung L; Salto-Tellez M; Chang KT
    J Clin Pathol; 2013 Nov; 66(11):985-91. PubMed ID: 23801497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.
    Greenall SA; Donoghue JF; Van Sinderen M; Dubljevic V; Budiman S; Devlin M; Street I; Adams TE; Johns TG
    Oncogene; 2015 Oct; 34(41):5277-87. PubMed ID: 25659577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sp1 regulates expression of MET, and ribozyme-induced down-regulation of MET in fibrosarcoma-derived human cells reduces or eliminates their tumorigenicity.
    Liang H; O'Reilly S; Liu Y; Abounader R; Laterra J; Maher VM; McCormick JJ
    Int J Oncol; 2004 May; 24(5):1057-67. PubMed ID: 15067326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
    Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
    Frampton GM; Ali SM; Rosenzweig M; Chmielecki J; Lu X; Bauer TM; Akimov M; Bufill JA; Lee C; Jentz D; Hoover R; Ou SH; Salgia R; Brennan T; Chalmers ZR; Jaeger S; Huang A; Elvin JA; Erlich R; Fichtenholtz A; Gowen KA; Greenbowe J; Johnson A; Khaira D; McMahon C; Sanford EM; Roels S; White J; Greshock J; Schlegel R; Lipson D; Yelensky R; Morosini D; Ross JS; Collisson E; Peters M; Stephens PJ; Miller VA
    Cancer Discov; 2015 Aug; 5(8):850-9. PubMed ID: 25971938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-Met antisense oligodeoxynucleotide inhibits growth of glioma cells.
    Chu S; Yuan X; Li Z; Jiang P; Zhang J
    Surg Neurol; 2006 Jun; 65(6):533-8; discussion 538. PubMed ID: 16720163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.
    Harshman LC; Choueiri TK
    Cancer J; 2013; 19(4):316-23. PubMed ID: 23867513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.